A DeCensi1, A Guerrieri-Gonzaga2, S Gandini3, D Serrano2, M Cazzaniga2, S Mora2, H Johansson2, E A Lien4, G Pruneri5, G Viale5, B Bonanni2. 1. Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan; Medical Oncology Unit, E.O. Ospedali Galliera, Genoa. Electronic address: andrea.decensi@galliera.it. 2. Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan. 3. Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. 4. Hormone Laboratory, Haukeland University Hospital; Section for Endocrinology, Institute of Medicine, University of Bergen, Bergen, Norway. 5. Division of Pathology, European Institute of Oncology; University of Milan School of Medicine, Milan, Italy.
Abstract
BACKGROUND: Studies have shown that Ki-67 response after short-term neoadjuvant aromatase inhibitors may predict recurrence in postmenopausal breast cancer, whereas its prognostic effect in premenopausal women is unknown. PATIENTS AND METHODS: We compared the prognostic and predictive value of baseline and post-treatment Ki-67 in 120 pre- and postmenopausal women with early-stage estrogen receptor-positive breast cancer who participated in a 4-week presurgical trial oftamoxifen. RESULTS: After 7.2 years of follow-up, women with post-treatment Ki-67 in the second (14%-19%), third (20%-29%) and top (≥30%) quartiles had a recurrence hazard ratio of 2.92 [95% confidence interval (CI) 0.95-8.96], 4.37 (1.56-12.25) and 6.05 (2.07-17.65), respectively, as compared with those in the bottom quartile (<14%) (P-trend = 0.001). The risk of invasive disease recurrence was 2.2% (95% CI 0.9-5.0) per point increase in baseline Ki-67 (P-trend = 0.076) and 5.0% (95% CI 2.3-7.7) per point increase in post-tamoxifen Ki-67 (P-trend < 0.001). The risk of death was 5.5 (95% CI 1.26-23.16) times higher in patients with post-drug Ki-67 ≥20% than in those with Ki-67 <20% (P-trend = 0.006). CONCLUSIONS:Ki-67 response after short-term neoadjuvant tamoxifen is a good predictor of recurrence-free survival and overall survival, further supporting its use as surrogate biomarker to personalize adjuvant treatment and to screen novel drugs cost-effectively.
RCT Entities:
BACKGROUND: Studies have shown that Ki-67 response after short-term neoadjuvant aromatase inhibitors may predict recurrence in postmenopausal breast cancer, whereas its prognostic effect in premenopausal women is unknown. PATIENTS AND METHODS: We compared the prognostic and predictive value of baseline and post-treatment Ki-67 in 120 pre- and postmenopausal women with early-stage estrogen receptor-positive breast cancer who participated in a 4-week presurgical trial of tamoxifen. RESULTS: After 7.2 years of follow-up, women with post-treatment Ki-67 in the second (14%-19%), third (20%-29%) and top (≥30%) quartiles had a recurrence hazard ratio of 2.92 [95% confidence interval (CI) 0.95-8.96], 4.37 (1.56-12.25) and 6.05 (2.07-17.65), respectively, as compared with those in the bottom quartile (<14%) (P-trend = 0.001). The risk of invasive disease recurrence was 2.2% (95% CI 0.9-5.0) per point increase in baseline Ki-67 (P-trend = 0.076) and 5.0% (95% CI 2.3-7.7) per point increase in post-tamoxifen Ki-67 (P-trend < 0.001). The risk of death was 5.5 (95% CI 1.26-23.16) times higher in patients with post-drug Ki-67 ≥20% than in those with Ki-67 <20% (P-trend = 0.006). CONCLUSIONS: Ki-67 response after short-term neoadjuvant tamoxifen is a good predictor of recurrence-free survival and overall survival, further supporting its use as surrogate biomarker to personalize adjuvant treatment and to screen novel drugs cost-effectively.
Authors: Jacek Gronwald; Andre Robidoux; Charmaine Kim-Sing; Nadine Tung; Henry T Lynch; William D Foulkes; Siranoush Manoukian; Peter Ainsworth; Susan L Neuhausen; Rochelle Demsky; Andrea Eisen; Christian F Singer; Howard Saal; Leigha Senter; Charis Eng; Jeffrey Weitzel; Pal Moller; Dawna M Gilchrist; Olufunmilayo Olopade; Ophira Ginsburg; Ping Sun; Tomasz Huzarski; Jan Lubinski; Steven A Narod Journal: Breast Cancer Res Treat Date: 2014-06-21 Impact factor: 4.872
Authors: Kevin Kalinsky; Katherine D Crew; Susan Refice; Tong Xiao; Antai Wang; Sheldon M Feldman; Bret Taback; Aqeel Ahmad; Serge Cremers; Hanina Hibshoosh; Matthew Maurer; Dawn L Hershman Journal: Cancer Invest Date: 2014-03-07 Impact factor: 2.176
Authors: Carol J Fabian; Bruce F Kimler; Carola M Zalles; Teresa A Phillips; Trina Metheny; Brian K Petroff; Thomas C Havighurst; KyungMann Kim; Howard H Bailey; Brandy M Heckman-Stoddard Journal: Cancer Prev Res (Phila) Date: 2015-09-21